Bellevue Asset Management, LLC Iovance Biotherapeutics, Inc. Transaction History

Bellevue Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.38 - $18.33 $497 - $1,429	-78 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$12.38 - $19.1 $173 - $267	-14 Reduced 15.22%	78 $1,000
Q4 2021 Feb 03, 2022	SELL	$16.55 - $27.63 $115 - $193	-7 Reduced 7.07%	92 $2,000
Q2 2021 Aug 09, 2021	SELL	$16.33 - $33.07 $146 - $297	-9 Reduced 8.33%	99 $3,000
Q1 2021 May 12, 2021	SELL	$28.67 - $52.59 $458 - $841	-16 Reduced 12.9%	108 $3,000
Q4 2020 Feb 11, 2021	SELL	$28.04 - $50.26 $1,149 - $2,060	-41 Reduced 24.85%	124 $6,000
Q3 2020 Nov 12, 2020	BUY	$27.75 - $36.3 $1,054 - $1,379	38 Added 29.92%	165 $5,000
Q1 2020 May 13, 2020	BUY	$19.54 - $38.85 $1,016 - $2,020	52 Added 69.33%	127 $5,000
Q4 2019 Feb 13, 2020	BUY	$17.95 - $29.41 $1,346 - $2,205	75 New	75 $2,000

313

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Bellevue Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bellevue Asset Management, LLC with notifications on news.